drugset / Trial / NCT06282458
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
Timeline
- Start
- 2024-04-29
- Primary completion
- 2025-04-11
- Completion
- 2025-08-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enobosarm | Small molecule | 3 mg | Oral |
| Subject | Enobosarm | Small molecule | 6 mg | Oral |
| Background | Semaglutide | Peptide | 1.7 mg | — |